First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

Timothy A. Yap,Minal A. Barve,Justin F. Gainor,Colin D. Weekes,Bruno Bockorny,Yawen Ju,Ryan Faucette,Sanela Bilic,Si Tuen Lee-Hoeflich,Guochen Song,Yung Chyung,Michelle Legler,Lu Gan,Johanna C. Bendell

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

2021

Timothy A. Yap
Minal A. Barve
Justin F. Gainor
Colin D. Weekes
Bruno Bockorny
Yawen Ju
Ryan Faucette
Sanela Bilic
Si Tuen Lee-Hoeflich
Guochen Song
Yung Chyung
Michelle Legler
Lu Gan
Johanna C. Bendell

TPS3146Background: Transforming growth factor-beta 1 (TGFβ1) is a key mediator of primary resistance to programmed cell death protein 1 (PD-1) pathway blockade. SRK-181 is a fully human, highly pot...

Keywords:

Cancer research
in patient
first in human
Mediator
Medicine
Blockade
Programmed cell death 1

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations